hotspot

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

advertisement

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

Totals $468 per year

Starter

$30

for 3 months, then $39/month

Then $39/month

Annual

$399

Save 15%

Save 15%

11+ Users

Custom

Savings start at 25%!

Savings start at 25%!

2-10 Users

$300

Annually per user

$300 Annually per user

Get unlimited access to award-winning journalism and exclusive events.